Instrument Inactif

Communiqués QSAM Biosciences, Inc.

Actions

QSAM

US74738N2027

Cours en clôture OTC Markets Autres places de cotation 00:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
8,3 ^USD	+7,10%		+3,75%	+36,07%

03/05	Telix Pharmaceuticals (Us) Inc. a conclu l'acquisition de QSAM Biosciences, Inc. (OTCPK:QSAM) auprès de Checkmate Capital Group LLC, Strategic Planning Assets Limited et d'autres.	CI
20/03	QSAM Biosciences, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER	16/04	AQ
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals	07/02	AQ
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee	14/11	AQ
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data	16/08/23	AQ
QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)	23/06/23	AQ
QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	14/06/23	AQ
QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center	23/05/23	AQ
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®	16/05/23	AQ
QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®	26/04/23	AQ
QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	11/04/23	AQ
QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer	06/04/23	AQ
QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer	05/04/23	AQ
QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)	04/04/23	AQ
QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22/03/23	AQ
QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023	20/03/23	AQ
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer	08/03/23	AQ
QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer	28/02/23	AQ
QSAM Biosciences Recruits the Ellis Fischel Cancer Center at the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam® for Bone Cancer	22/02/23	AQ
QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	25/01/23	AQ
QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023	23/01/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués QSAM Biosciences, Inc.

Actions

QSAM

US74738N2027

Communiqués

Filtres